This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Les Laboratoires Servier, Pharmacyclics, Inc.. Active years: 2014.
Company Filing History:
1 out of 295 
1 out of 194 
Years Active: 2014
Title: Marylore Chenel: Innovator in Cancer Treatment
Introduction
Marylore Chenel is a notable inventor based in Paris, France. She has made significant contributions to the field of cancer treatment through her innovative patent. Her work focuses on improving therapeutic regimes for patients battling cancer.
Latest Patents
Marylore holds a patent for an administration regime for N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide. This compound is characterized by its unique administration schedule, which involves administering the treatment for four consecutive days, followed by three days without the compound. This method is designed to enhance the effectiveness of cancer treatments while avoiding specific chemotherapy regimens, such as FOLFOX.
Career Highlights
Throughout her career, Marylore has worked with prominent companies in the pharmaceutical industry. She has been associated with Pharmacyclics, Inc. and Les Laboratoires Servier, where she has contributed her expertise in drug development and cancer therapies. Her innovative approach has garnered attention in the medical community.
Collaborations
Marylore has collaborated with esteemed colleagues, including Anne Jacquet-Bescond and Ioana Kloos. These partnerships have allowed her to expand her research and enhance the impact of her inventions in the field of oncology.
Conclusion
Marylore Chenel is a pioneering inventor whose work in cancer treatment exemplifies innovation in the pharmaceutical industry. Her dedication to improving patient outcomes through her patented methods is commendable.